⌘K
Loading ticker…
As of 2026-08-24, Alnylam Pharmaceuticals, Inc. (ALNY) has a 3-month relative strength percentile of 19 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 37. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.7%, relative volume 0.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ALNY is in a stage 4 downtrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -11.1% / -28.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
ALNY is held by 64 ETFs as of May 2026. Top owner: CGGR at 0.76% weight, $185M notional. Top 3 carry $475M.
Held by 223 ETFs · $7.6B across latest filings · largest weight 4.84% (PBE).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| CGGR | 0.76% | $185M | −0.16 pp |
| QQQMInvesco NASDAQ 100 ETF | 0.18% | $170M | −0.06 pp |
| VHTVanguard Health Care ETF | 0.63% | $120M | −0.02 pp |
| SCHGSchwab U.S. Large-Cap Growth ETF | 0.14% | $85M | −0.03 pp |
| VONGVanguard Russell 1000 Growth ETF |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.12% |
| $63M |
| −0.03 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.06% | $42M | −0.01 pp |
| GSLC | 0.17% | $27M | +0.03 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.05% | $24M | −0.01 pp |
| TQQQProShares UltraPro QQQ | 0.05% | $21M | −0.09 pp |
| QLDProShares Ultra QQQ | 0.11% | $16M | −0.07 pp |
Showing 10 of 64 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALNY Jan avg: -3.52% median: -7.20% win: 25% σ: 13.23% n: 4 2022-04-12 → 2026-07-31 | ALNY Feb avg: -9.66% median: -10.84% win: 0% σ: 6.02% n: 4 2022-04-12 → 2026-07-31 | ALNY Mar avg: 3.09% median: 2.01% win: 50% σ: 4.96% n: 4 2022-04-12 → 2026-07-31 | ALNY Apr avg: -5.69% median: -3.68% win: 0% σ: 5.75% n: 5 2022-04-12 → 2026-07-31 | ALNY May avg: 0.71% median: -2.43% win: 40% σ: 9.26% n: 5 2022-04-12 → 2026-07-31 | ALNY Jun avg: 17.81% median: 7.07% win: 80% σ: 26.38% n: 5 2022-04-12 → 2026-07-31 | ALNY Jul avg: -2.69% median: -2.28% win: 40% σ: 18.72% n: 5 2022-04-12 → 2026-07-31 | ALNY Aug avg: 17.80% median: 12.23% win: 100% σ: 19.23% n: 4 2022-04-12 → 2026-07-31 (current) | ALNY Sep avg: -1.70% median: -0.51% win: 50% σ: 6.70% n: 4 2022-04-12 → 2026-07-31 | ALNY Oct avg: -3.45% median: -1.53% win: 50% σ: 7.71% n: 4 2022-04-12 → 2026-07-31 | ALNY Nov avg: 2.79% median: 2.69% win: 50% σ: 7.18% n: 4 2022-04-12 → 2026-07-31 | ALNY Dec avg: 0.65% median: 0.36% win: 50% σ: 12.08% n: 4 2022-04-12 → 2026-07-31 |